Douglas K. Marks

732 total citations
26 papers, 302 citations indexed

About

Douglas K. Marks is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Douglas K. Marks has authored 26 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Douglas K. Marks's work include Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (6 papers) and HER2/EGFR in Cancer Research (4 papers). Douglas K. Marks is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (6 papers) and HER2/EGFR in Cancer Research (4 papers). Douglas K. Marks collaborates with scholars based in United States, Canada and Switzerland. Douglas K. Marks's co-authors include Stephen E. Goldstone, Yvonne M. Saenger, Robyn D. Gartrell, Thomas D. Hart, Basil A. Horst, Bret Taback, Emanuelle M. Rizk, Kimberly M. Komatsubara, Evan Rosenbaum and Shahzad Raza and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Douglas K. Marks

23 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas K. Marks United States	11	184	99	71	64	62	26	302
Ruth A. White United States	8	200 1.1×	202 2.0×	121 1.7×	47 0.7×	41 0.7×	14	447
Hideyuki Kuriyama Japan	11	219 1.2×	144 1.5×	229 3.2×	51 0.8×	64 1.0×	21	415
Cigdem Ussakli United States	8	155 0.8×	111 1.1×	26 0.4×	72 1.1×	21 0.3×	10	308
Elizabeth Gaughan United States	10	261 1.4×	124 1.3×	188 2.6×	79 1.2×	23 0.4×	28	395
Beny Shapiro Israel	5	195 1.1×	157 1.6×	158 2.2×	35 0.5×	35 0.6×	6	337
Zunling Li China	7	147 0.8×	136 1.4×	98 1.4×	28 0.4×	17 0.3×	11	311
Tenny Mudianto United States	8	181 1.0×	196 2.0×	111 1.6×	60 0.9×	23 0.4×	9	406
Joseph M. Obeid United States	9	252 1.4×	132 1.3×	160 2.3×	60 0.9×	28 0.5×	13	371
Simone K. Bendtsen Denmark	10	84 0.5×	55 0.6×	56 0.8×	22 0.3×	37 0.6×	16	252
H Sasaki Japan	10	122 0.7×	136 1.4×	21 0.3×	75 1.2×	43 0.7×	19	346

Countries citing papers authored by Douglas K. Marks

Since Specialization

Citations

This map shows the geographic impact of Douglas K. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas K. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas K. Marks more than expected).

Fields of papers citing papers by Douglas K. Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas K. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas K. Marks. The network helps show where Douglas K. Marks may publish in the future.

Co-authorship network of co-authors of Douglas K. Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas K. Marks. A scholar is included among the top collaborators of Douglas K. Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas K. Marks. Douglas K. Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Nancy, Dirk F. Moore, Kari B. Wisinski, et al.. (2025). Abstract P2-07-21: A phase II study of pembrolizumab plus fulvestrant in ER positive, HER2 negative advanced/metastatic breast cancer patients. Clinical Cancer Research. 31(12_Supplement). P2–7.

Yap, Timothy A., Rachel N. Grisham, John Hamm, et al.. (2023). First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 3010–3010. 36 indexed citations

Rimawi, Mothaffar F., Erika Hamilton, Sara A. Hurvitz, et al.. (2023). Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 1092–1092. 7 indexed citations

Vanguri, R., Kathleen Fenn, Qi Wang, et al.. (2022). Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer. Clinical Breast Cancer. 22(6). 538–546. 10 indexed citations

Kim, Gina, Panagiota S. Filippou, David Entenberg, et al.. (2021). The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy. Frontiers in Immunology. 12. 654877–654877. 21 indexed citations

Mirsadraei, Leili, et al.. (2021). Anal Cancer with Mediastinal Lymph Node Metastasis. PubMed. 8(3). 134–137. 1 indexed citations

Kucharczyk, John, Maryann Kwa, Magdalena Plašilová, et al.. (2021). Risk for SARS-CoV-2 infection in patients with breast cancer treated with chemotherapy, biologic therapy or active surveillance: Patient outcomes from multicenter institution in New York.. Journal of Clinical Oncology. 39(15_suppl). 1513–1513. 1 indexed citations

Marks, Douglas K., et al.. (2021). Bone marrow necrosis and fat embolism syndrome: a near fatal complication in previously undiagnosed sickle beta + thalassaemia. BMJ Case Reports. 14(1). e238317–e238317. 1 indexed citations

Gartrell, Robyn D., Andrew Chen, Emanuelle M. Rizk, et al.. (2020). Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma. Cancer Research. 80(5). 1078–1087. 17 indexed citations

10.

Marks, Douglas K., Robyn D. Gartrell, Margueritta El Asmar, et al.. (2020). Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Frontiers in Oncology. 10. 968–968. 20 indexed citations

11.

Trager, Megan H., Robyn D. Gartrell, Emanuelle M. Rizk, et al.. (2020). Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec. Melanoma Research. 30(4). 410–415. 5 indexed citations

12.

Gartrell, Robyn D., Douglas K. Marks, Emanuelle M. Rizk, et al.. (2019). Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma. Clinical Cancer Research. 25(8). 2494–2502. 17 indexed citations

13.

Steinberg, Amir, Janet H. Van Cleave, Erin Moshier, et al.. (2019). The Effect of Glucose Levels Prior to Hematopoietic Cell Transplantation on Post-Transplant Complications and Health Resource Utilization. International Journal of Hematology-Oncology and Stem Cell Research. 13(3). 122–131. 2 indexed citations

14.

Gartrell, Robyn D., Zoë Blake, Douglas K. Marks, et al.. (2018). 1192 Distinguishing melanophages from melanoma in metastatic melanoma treated with t-vec: A clinical application of quantitative multiplex immunofluorescence. Journal of Investigative Dermatology. 138(5). S202–S202. 2 indexed citations

15.

Blake, Zoë, Douglas K. Marks, Robyn D. Gartrell, et al.. (2018). Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. Journal for ImmunoTherapy of Cancer. 6(1). 25–25. 29 indexed citations

16.

Kalinsky, Kevin, Joseph A. Sparano, Xiaobo Zhong, et al.. (2018). Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. Clinical & Translational Oncology. 20(11). 1474–1483. 19 indexed citations

17.

Komatsubara, Kimberly M., Robyn D. Gartrell, Thomas D. Hart, et al.. (2018). Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.. Journal of Clinical Oncology. 36(15_suppl). 9570–9570. 2 indexed citations

18.

Lopez, Adriana T., Robyn D. Gartrell, Kimberly M. Komatsubara, et al.. (2018). The Role of Oncolytic Viruses in the Treatment of Melanoma. Current Oncology Reports. 20(10). 80–80. 37 indexed citations

19.

Steinberg, Amir, Janet H. Van Cleave, Douglas K. Marks, et al.. (2015). Glucose Levels Prior to Stem Cell Transplant Affect Length of Stay and 90-Day Readmission Rates. Blood. 126(23). 2117–2117. 2 indexed citations

20.

Marks, Douglas K. & Stephen E. Goldstone. (2011). Electrocautery Ablation of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Negative and HIV-Positive Men Who Have Sex With Men. JAIDS Journal of Acquired Immune Deficiency Syndromes. 59(3). 259–265. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact